Skip To Main Content
Brian Lin on Muck Rack

Brian Lin

Verified
Washington, D.C.
As seen in: EurekAlert!, Medium, Color Research & Application, Nature, Wiley Online Library, Elsevier, Frontiers, ZDNet, JAMA (The Journal of the American Medical Association), Seeking Alpha, UBC News and
@EurekAlert editorial director, lover of #arts, #scicomm and #DEI, RT's aren't endorsements. All views are my own. 🏳️‍🌈

Get in touch with Brian

Contact Brian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

We’ve Made a Mess of Masculinity, but I Believe It Can Change

|
By Brian Lin Verified
| Electric Literature Verified
My partner and I go to the movies. The theater and our conversations after, on the drive home or at the bar where we’re regulars—this routine is our most consistent intimacy. We are in couples therapy, have been for many years now. The current cadence is once a month. In this season of my 30s, dry and lacking direction like I’m in the deep desert of Arrakis, a month can feel like a year. So much effort but no change. All pain and no gain. Powerless, like many men tell us they feel.
Open in Who Shared Issue with article?

Around the Helix: Cell and Gene Therapy Company Updates – January 21, 2026 | CGTlive®

|
By Brian Lin Verified, Isabella Ciccone, Noah Stansfield, Martin Harp
| CGTLive
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive®’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Open in Who Shared Issue with article?

Ocugen Posts Positive Preliminary Phase 2 ArMaDa Trial Data of OCU410

|
By Brian Lin Verified, Isabella Ciccone, Steven W Pipe, Noah Stansfield
| CGTLive
This article originally appeared on our sister site, Ophthalmology Times. Ocugen has reported encouraging preliminary 12‑month findings from its phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5‑RORA) as a potential treatment for geographic atrophy (GA) associated with dry age-related macular degeneration (dAMD). OCU410 is an investigational gene therapy administered via intravitreal injection.
Open in Who Shared Issue with article?
See all 94 licensed articles (106 Total)